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In the early 1990s, the EU’s proposed bioeconomic agenda provoked ethical concerns among its
citizenry. In response to the political impasse between economic and ethical imperatives, as well
as the perceived lack of democratic legitimacy, the EU established an expert bioethics advisory
body, known as the European Group on Ethics in Science and New Technologies (EGE). Situated
at the boundary between law, bioethics and economic policy, the EGE plays an ambiguous role in
the governance of biotechnologies in the EU. To elucidate the nature of its role and influence, this
paper considers the EGE as an integral element of a broader web of governance spanning EU and
Member State institutions. Using as a case study the emerging controversy surrounding commer-
cial cord blood banking, we explore whether the EGE and its ethical opinions on this matter have
contributed to the democratic legitimacy of the EU.
1. Introduction
The complex institutional and operational arrangements of
the EU often provoke claims of a lack of democratic legit-
imacy (Weiler et al. 1995; Heretier 1999; Kohler-Koch
and Rittberger 2007; Menon and Weatherill 2007;
Bellamy 2010). From this perspective, the governance
of biotechnologies in the EU is problematic. While
biotechnologies are seen as ‘key for the future competitive
development of the Community’ (European Commission
1991: 1), many are recognised by the European
Commission, since at least the early 1990s,1 as ethically
contentious, generating a tension between some citizens
and the European Commission’s vision of their increased
commercialisation. In response, and seeking in part to
rectify the (perceived) democratic deﬁcit, the European
Commission created an expert bioethics advisory body in
1991, now known as the European Group on Ethics in
Science and New Technologies (EGE).
Situated at the boundary between law, bioethics, and
economic policy, the EGE plays an ambiguous role in
the EU governance of biotechnologies. Previous studies
highlight the EGE’s uncertain place in both the EU legal
order, given that it has no ﬁrm basis in the constituent
treaties or legislative structures (Busby et al. 2008) and
‘involves a blurring of normative moral and legal orders’
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(Plomer 2008: 840); and the EU political order, as a broker
at the boundary between economic and cultural pressures
on decision-making legitimacy (Salter and Jones 2002a,b;
Jasanoff 2005). With the exception of our own previous
work (Busby et al. 2008), these studies focus on the con-
tribution of EGE opinions to determining the ethical con-
straints on human embryonic stem cell research for the
Biotechnology Directive (where the EGE’s inﬂuential
role is documented, and which confers the EGE’s
mandate to evaluate ‘all ethical aspects of biotechnology’)
or for the Framework Programmes. In this paper, using as
a case study EGE Opinion No. 19 on the ‘Ethical aspects
of umbilical cord blood banking’, we examine the nature
of the EGE’s inﬂuence in the governance response to the
emerging controversy around commercial cord blood stem
cell banking in Europe. Our focus on this Opinion,
published in 2004, reﬂects its place in responding to wide-
spread ethical concerns within the EU about the legitimacy
of commercial cord blood banking and the development of
the Tissues and Cells Directive (European Parliament and
the Council of the European Union 2004), where the EGE
had the potential to inﬂuence the ethical parameters
for standards of quality and safety of human tissues
and cells (which in this context include cord blood) for
transplantation.
1.1 Aims and methods
The work of bioethics advisory bodies has grown as gov-
ernments have recognised the new challenges posed by
recent developments in the biotechnologies and the need
to engage the ethical concerns (both actual and perceived)
of publics. Much analysis of such bodies has focused on
their role in advising national governments, particularly in
the USA, where such bodies are well established. Kelly’s
(2003) analysis of the ‘boundary work’ of the US Human
Embryo Research Panel ﬁnds that these bioethics groups
perform ethical debate about issues that cannot be
resolved through other political mechanisms. In the EU,
the study by Hervey and Black (2005) on the governance of
stem cell research highlighted the role of ethical norms and
declarations. They concluded that such declarations can be
considered to be an inﬂuential form of soft governance.
Turning to the EGE speciﬁcally, there has been criti-
cism by legal scholars of its lack of a clear constitu-
tional basis and its unclear relationship with the
European Commission. Plomer et al. (2006) write of a
blur between legal and moral reasoning that may afﬂict
the EGE, and question its authority and credibility. We
have previously concluded that the EGE’s constitutional
status is at best ‘grey’ given that it has no ﬁrm basis in the
EU’s constituent treaties, or the legislative structures de-
veloped to enhance the legitimacy, transparency, account-
ability and representativeness of EU legislative and
executive decision-making (Busby et al. 2008). There are,
though, more positive views: Jasanoff (2005: 218) observes
that the EGE’s mandate is indicative of a distinctive gov-
ernance framework characterised by the ‘permeability of
the boundary between law and ethics’.
Drawing on perspectives from law, political science and
sociology, we investigate how the EGE operates within a
broader network of institutions and relations that govern
biotechnologies in the EU. We consider the EGE as an
integral element in a ‘web of governance’—an analytic
term used to resolve our earlier difﬁculty in fully explain-
ing, through a narrow legal approach, the role or inﬂuence
of the EGE in law, speciﬁcally on the legislative process
surrounding the Tissues and Cells Directive (Busby et al.
2008). We searched the relevant legislative databases but
found no mention of Opinion No. 19. In looking at the
EGE as part of a ‘web of governance’, rather than in more
linear, top-down or dichotomous (law/ethics; law/politics)
terms, we develop a multilayered understanding of the gen-
eration of, and role played by, ofﬁcial EU ethics advice,
which takes account of the interactions between institu-
tional actors at the EU and national levels.
The development of biotechnology policy has posed par-
ticular governance challenges as it involves specialist tech-
nical and ethical domains beyond the competences and
understanding of EU policy-makers. The pace of biotech-
nological development, and the sensitive social and ethical
issues it raises, has forced EU policy-makers to re-evaluate
traditional concepts of regulation. Creating a web of gov-
ernance around these issues is seen as a way to develop
more informal yet continuous linkages with the required
sources of expertise and knowledge. Alongside technical
groups and networks of policy advisors, bioethics
advisory groups, such as the EGE, play a signiﬁcant part
in advising on the direction, value, and legitimacy of de-
velopments in science and technology.
This paper stems from a small project that investigated
the role played by the EGE in the governance response to
ethical problems associated with commercial cord blood
banking in the EU. Documentary analysis of the social
scientiﬁc literature encompassing bioethics advisory
groups, EGE publications, legislative proposals,
Commission strategies, European Parliament proceedings
and outputs of the National Ethics Committees was
undertaken to trace the broader impact of (and inﬂuences
on) the EGE.
Eight focused, semi-structured interviews were con-
ducted with former and current members of the EGE in-
strumental in the development of Opinion No. 19 and with
the former and current heads of the EGE Secretariat.2
Access to the current EGE members was managed by the
head of the Secretariat. The EGE deliberates in private,
and requests to attend and observe its internal procedures
were denied. Permission was granted to interview the
chairperson, the two rapporteurs and the head of the
Secretariat. Former members were interviewed at their
convenience.
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We begin by tracing the evolution of the EGE’s
mandates, membership and methods in this context. We
then outline the governance problem of tissue banking in
Europe, and analyse the EGE’s response. The nature of the
EGE’s role and inﬂuence in a web of bioethical governance
is then considered. We conclude by examining whether the
EGE’s activities and its opinions have helped to broaden
the legitimacy base of EU decisions.
2. Evolution of the EGE: Its mandates,
membership and methods
2.1 Mandates
The Group of Advisors on the Ethical Implications of
Biotechnology (GAEIB) was established by the
Commission in 1991 to provide ‘neutral, independent,
pluralist and multidisciplinary’ advice to EU decision-
makers on the ethical dimensions of biotechnologies
(EGE 2009). The GAEIB’s mandate echoed the rationale
for its establishment to support the regulatory process,
including the Biotechnology Directive (98/44/EC on the
legal protection of biotechnological inventions) that was
then being contested for ethical reasons by the European
Parliament (EGE 1991). The GAEIB published two early
Opinions that inﬂuenced the development of the Directive
and the terms of its eventual adoption.3 In recognition of
its role as an ethical arbiter in the bio-political disputes
surrounding the Directive, Article 7 confers ‘ofﬁcial
status’ upon the EGE, the GAEIB’s successor, by
granting it a continuing mandate to evaluate ‘all ethical
aspects of biotechnology’ (European Parliament and the
Council of the European Union 1998).
A Commission Decision established the EGE in
December 1997 (European Commission 1997). Under its
ﬁrst mandate (1998–2000), the expanding role of the EGE,
as compared to the GAEIB, is evident from the description
of its main objectives by Commission President Jacques
Santer:
. . . to help break down barriers in ﬁelds which require a
multi-disciplinary approach, not only scientiﬁc and legal but
also philosophical, sociological and economic; to provide
European decision-makers with clear and up-to-date basic
information, enabling them to be properly informed in
carrying out their duties; to promote dialogue that stimulates
mutual tolerance so that all viewpoints can be expressed before
the Community authorities decide on appropriate regulations.
(EGE 1998)
In this description, the EGE is the servant of ‘European
decision-makers’, not solely the Commission.4 Requests
for opinions could now also be made by the European
Parliament and the Council of Ministers. Whereas the
GAEIB’s task was simply to keep EU citizens informed,
the EGE has an expanded role of promoting dialogue and
actively encouraging at least tolerance of new technologies.
The EGE’s mandate for 2000–5 was also established by
an informal Commission Communication (EGE 2007).
Yet its political legitimacy was strengthened when the
Commission elevated its Secretariat to membership of
the Bureau of European Policy Advisers (BEPA), where
it reports directly to the President of the Commission
and acts under his authority (EGE 2007). BEPA
provides the President, his College of Commissioners and
the Directorates-General with strategic upstream policy
advice on issues relevant to the President’s policy
agenda. The EGE also began formally to network with
the National Ethics Councils Forum (comprising represen-
tatives of the National Ethics Committees of the Member
States) to exchange information, experience and best
practice on ethical issues related to science. Via its links
with BEPA, this network has extended to civil society or-
ganisations including think tanks, academia, and faith
communities.
During this period, the Tissues and Cells Directive
(2004/23/EC) on ‘Setting standards of quality and safety
for the donation, procurement, testing, processing, pres-
ervation, storage and distribution of human tissues and
cells’ was enacted (European Parliament and the Council
of the European Union 2004). In developing its proposals
for this Directive, the Commission referred explicitly to
the EGE’s Opinion No. 11 on the ‘Ethical aspects of
human tissue banking’, expressly stating that its
‘proposal for a Directive reﬂects the recommendations
put forth by the EGE’, and whose opinion will be re-
spected in the future whenever necessary (European
Commission 2002b). The ﬁnal text of the Directive, espe-
cially its preamble, explicitly features ethical principles
related to voluntary and unpaid donation found in the
EGE Opinion.
A Commission Decision of May 2005 marks the ﬁrst
formal legal document establishing a mandate (2005–10)
for the EGE (European Commission 2005a). Under this
third mandate, the EGE developed links, via its
Secretariat, with the Commission’s Inter Service Platform
which provides coordination across all 19 Commission
services.5 The EGE Secretariat coordinates the Inter
Service Group on Ethics and EU Policies to facilitate the
exchange of information and coordinate actions on ethics
both within and external to the European Commission.
In 2009, BEPA initiated the International Dialogue
on Bioethics, jointly chaired by the President of the EGE
and the Chairperson of the National Ethics Councils
Forum, to facilitate information sharing between 42
European and non-European National Ethics Committees.
2.2 Membership
The EGE has evolved incrementally in both size and scope
from a modest ad hoc advisory body to include wider ex-
pertise andmore established members. With six members at
its inception, the GAEIB expanded to nine in 1994.
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Its members came from the disciplines of law, science,
medicine, philosophy and theology and served terms of
just two years. From 1998, the EGE’s 12 members,
including experts in sociology and informatics, initially
served terms of three years before increasing to four from
2000 (see Table 1 for a list of members who contributed to
the development of Opinion No. 19, published in 2004).
Membership expanded to 15 in 2005 and encompassed add-
itional expertise in food safety and pharmacology.
Since the Commission Decision of May 2005, a list of
EGE members is published in the Ofﬁcial Journal
(European Commission 2005b). Until recently, the docu-
mentary record states that EGE members were appointed
by the Commission. However, in its third mandate, this
power was transferred solely to the Commission
President. When the Commission was questioned about
this change, it responded that, informally, this had always
been the case and this document merely formalised the pro-
cedure (European Parliament 2006b). New members of the
EGE are recruited through an open call on the EGE
website. Additional applications from other channels are
also taken into consideration (European Commission
2005c). What these ‘other channels’ are is not entirely clear.
Members must have a university degree in ethics,
philosophy, theology, law or science and relevant,
internationally recognised high-level experience
(European Parliament 2006a). They are expected to
attend at least four meetings a year (European
Commission 2005c). There is no legal obligation on
members to make statements of their interests, or even to
declare any conﬂict of interest in a particular Opinion.6
They are appointed ad personam; that is, they are inde-
pendent and represent their own views and conscience.7
However, the President is concerned with balance of geo-
graphical origin, gender and areas of expertise (Interview
(c) 20 June 2007; Interview 24 October 2007). This suggests
a representative element in the rationale behind the selec-
tion of the EGE’s membership: different geographical
constituencies represented in the EGE might map to
broader cultural or historical outlooks that differ with
respect to ethics. But at present, the need to ensure such
representation (or alternatively, an explanation of why this
is not necessary) is not codiﬁed.
2.3 Methods
While the EGE is formally obliged to agree its work with
the Commission President, it can initiate its own Opinions,
and in general it creates its own rules of procedure
(European Commission 2005c). Under its 2000–5
mandate, the EGE was not formally obliged to establish
close links with the Commission departments involved in
Table 1. Membership of EGE during the development of Opinion No. 19
Name Member State Professional afﬁliation Expertise
Prof. Go¨ran Hermere´n (President) Sweden Professor of Medical Ethics, Faculty of Medicine,
Lund University
Philosophy, medical ethics
Prof. Linda Nielsen
(Vice-President)
Denmark Professor of Law, Rector of University of Copenhagen Bio-law
Prof. Nicos C. Alivizatos Greece Professor, Department of Public Law, Faculty of Law,
University of Athens
Public law
Prof. Inez De Beaufort Netherlands Professor of Health Care Ethics, Medical Faculty,
Erasmus University, Rotterdam
Theology, health care ethics
Prof. Rafael Capurro Germany Professor of Information Management and
Information Ethics, Fachhochschule Stuttgart,
Hochschule der Medien, University of Applied
Sciences
Philosophy, information ethics
Prof. Yvon Englert Belgium Head of Fertility Clinic, and Professor of Medical
Ethics and Deontology, Free University of Brussels
Obstetrics and gynecology
Prof. Catherine Labrusse-Riou France Professor of Law, University of Paris,
Panthe´on-Sorbonne
Private law, family law
Dr Anne McLaren UK Research Associate at Wellcome CRC Institute,
Cambridge
Genetics, reproductive biology,
developmental biology
Prof. Pere Puigdome`nech Rosell
(Rapporteur)
Spain Research Professor at Department for Molecular
Genetics, and Director of Institut de Biologia
Molecular de Barcelona, CSIC
Molecular genetics
Prof. Stefano Rodota Italy Professor of Civil Law, University of Rome, Chairman
of Italian Data Protection Authority, Chairman of
European Group of Data Protection Authorities
Civil law
Prof. Gu¨nter Virt (Rapporteur) Austria Professor of Theology, Institute of Catholic Moral
Theology, University of Vienna
Theology
Prof. Peter Whittaker Ireland Professorial Fellow, Centre for Economic and Social
Aspects of Genomics, Lancaster University, UK
Molecular genetics, biology
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the topic under consideration or to organise public
round-table debates to promote dialogue and improve
transparency (although these activities have been compul-
sory since the 2005–10 mandate), nor was it under any
formal obligation to consult either other institutional
actors within the EU or its Member States, stakeholders,
or wider European publics. The group has adopted a
number of ad hoc practices, usually at the discretion of
the chairperson, including consulting experts and stake-
holders representing a range of scientiﬁc, legal and
ethical opinions, initiating studies and setting up working
groups to collate scientiﬁc and technical information. In
practice, the EGE also takes note of opinions and recom-
mendations of National Ethics Committees in the Member
States.8 These interactions have expanded with each sub-
sequent mandate. The range of information gathered is
distilled to identify the salient ethical principles with the
aim of achieving group consensus (Interview 19 June 2007;
Interview (a) 20 June 2007; Interview (c) 20 June 2007;
Interview 24 October 2007). Where consensus is not
reached, a dissident opinion is appended to the main
opinion, and each is signed by their respective supporters.
The EGE publishes its Opinions electronically.
However, its working sessions are private. Accordingly,
the internal documents of the EGE cannot be accessed,
even from within the Commission (Interview 24 October
2007). Nevertheless, the EGE has developed some general
principles of transparency, keeping proceedings as open as
it deems necessary, for instance, with round-table discus-
sions, and the electronic publication of these (since late
2005), and other materials received by the EGE.
Since its inception in 1991, the GAEIB/EGE has pub-
lished 25 Opinions covering the spectrum of bioethical
issues. Eight of these address the collection and deploy-
ment of human tissues and cells.
2.4 An integral component of a web of governance?
The Group’s evolving mandates, membership and methods
are indicative of the fact that the EGE has increasingly
operated in a broader network of institutions and relations
that construct, negotiate and govern biotechnologies in the
EU. Establishing its own legitimacy was an acknowledged
challenge. In its ﬁrst general report (EGE 2001: 2),
President Noe¨lle Lenoir enquired:
How was the new European body on ethics . . . to establish
its legitimacy not only with the different European institutions
but also in relation to the many interest groups concerned?
Under Lenoir’s presidency, the EGE seemed keen to gain a
more ofﬁcial status, recognising that mere attention does
not in itself play a legitimating role:
. . . it is high time to put an end to the current, paradoxical
situation. On the one hand, the EGE is increasingly well
known outside the Commission. International general and
specialised media regularly report on its work. Students write
dissertations and theses examining its work. When the Group
pays its traditional six-monthly visit to the country holding the
EU presidency it is received by the highest national authorities.
Yet it does not have genuine recognition within the
Commission. Its status remains uncertain. A Community
decision should enable it to be given a more ofﬁcial and, at the
same time, clearer status. (EGE 2001: 18)
Its Secretariat does not see any lack of clarity concerning
the EGE’s status as an independent advisory body
(Interview (c) 20 June 2007), within a web of governance
interactions with other bodies within the EU and its
Member States. We now outline the challenge of tissue
banking governance, before considering the EGE’s inﬂu-
ences over this challenge.
3. Tissue banking in Europe: An ethical
controversy
The use of human tissues and cells for transplantation has
expanded greatly in recent years, and cooperation is
required between tissue banks in order to achieve the
best ‘match’ of tissue type for some patients (Rubinstein
2006). This has led to the establishment of a number of
registries (e.g. EuroCord and NetCord) that facilitate the
international exchange of such tissues.
Public tissue banks in European countries have, since
their inception in the post-World War II years, been
associated with particular social values and relationships
bound by ‘ethical citizenship, altruism and communitarian
values’ (Waldby 2006: 57).9 Since the late 1980s, the EU
has sought to encode these widely held values in its formal
recommendations on blood and tissue banking (see Hervey
and McHale (2004: 343–7) and Farrell (2006)). For
instance, ‘the philosophy of voluntary and unpaid dona-
tion . . . altruism of the donor, and solidarity between
donor and recipient’ is restated in Directive 2004/23/EC
(European Parliament and the Council of the European
Union 2004: recital 18). The idea of a market in private
tissue banking challenges this longstanding emphasis on
the importance of common good or solidarity in this
domain.
The ﬁrst public and private umbilical cord blood banks
began to emerge in the 1990s following the discovery that
cord blood stem cells could be used in transplant medicine
as a less immunologically sensitive and less invasive alter-
native to bone marrow cells. Since the ﬁrst pioneering
transplantation of cord blood cells in France in 1988 to
treat Fanconi’s anaemia in a child, cord blood has been
successfully transplanted in thousands of children for
blood disorders (Gluckman et al. 1989). Similar progress
in adult transplantations has followed recent developments
in the use of double units to increase the cell volume
(NetCord 2007).
From the point of view of physicians working in the
ﬁeld, the arrival of large-scale international private cord
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blood banks in Europe was cause for widespread concern.
They considered that the likelihood of an individual
needing a cord blood transplant was extremely low, and
its future ‘potential’ to cure a range of disorders specula-
tive (World Marrow Donor Association 2006). Because
most private banks do not publicly register their
holdings, these are not made available to patients who
might need them.
A further problem is posed by private banks’ marketing
activities, and the promissory dynamic that is inherent in
their business model. Bearing in mind that autologous
transplants and cell therapies—where the patient’s own
cells are used—would be of value only if new applications
were developed for cord blood stem cells, what is being
marketed is less a product or service than a promise of
possibility. This marketing may also stoke insidious
fears, as some clinicians and Members of the European
Parliament (MEPs) have claimed: parents are prompted
to focus on the possibility of the severe illnesses that
might, rarely, result in stem cell transplants being needed
for a child, and on the possibility that matched cells would
not be available for their child.
Paradoxically, given that much of the opposition to
private banks is posited on a lack of public utility, there
is also the problem of the inequitable divide that might
arise if progress in stem cell therapies enables the effective
use of cells predeposited by individuals. If barriers to the
use of autologous stem cell therapies were to be overcome,
parents who could afford to bank their child’s cord blood
stem cells would have been able to purchase an advantage.
This prospect of inequitable access to future stem cell
therapies adds a further edge to the objections.
Within the Commission, the Directorate-General for
Health and Consumer Protection is primarily responsible
for overseeing EU policy on the use of human tissues and
cells in medicine. Speciﬁcally, Directive 2004/23/EC and its
two implementing Directives are the basis for its actions
for work on tissues and cells. Contrary to what might be
expected from the account of the governance context
above, in which ethics and values pose key challenges,
much of the Directorate-General for Health and
Consumer Protection’s work concerns the ‘technical’
aspects of setting basic standards for tissues and cells, so
that when they are exchanged across borders, minimum
standards, for example of testing for infection and contam-
ination, will apply. We consider below the role that the
EGE’s Opinion on cord blood banking has played in the
EU’s governance response to tissue banking.
4. EGE and the governance response to
tissue banking in the EU
The arrival of the private US-based bank Cryo-Cell in
Europe in 2000 provoked complaint from politicians and
clinicians who had been sensitised by earlier controversies
to commercial involvement in the biotechnology ﬁeld.
During a European Parliamentary session in April 2001
Dutch MEP, Ria Oomen-Ruijten, questioned the legitim-
acy of Cryo-Cell’s ‘direct to parents’ advertising methods
and the therapeutic claims used to market its services, sug-
gesting it was a matter for the EGE to consider. She
labelled it a ‘campaign [that] plays on the concern of pro-
spective parents to prevent illness, and the fear of death’
(European Parliament 2001b). Her question echoed
broader concerns about consumer protection and public
health raised in the debates on the Biotechnology
Directive. Although hesitant to intervene in these enter-
prises where they are allowed by Member States
(European Parliament 2001a), the Commission eventually
agreed that commercial cord blood banking raises serious
ethical questions and, in August 2001, instructed the EGE
to prepare an Opinion on the ethical aspects of this type of
activity (European Parliament 2002).
4.1 EGE Opinion on ‘Ethical aspects of umbilical
cord blood banking’
The EGE published Opinion No. 19 in March 2004. The
topic is unusually speciﬁc, for the EGE, but concomitant
to its broader work on human tissues and cells. Whilst the
thrust of the Opinion is critical of commercial cord blood
banking, it does not recommend prohibition. The back-
ground section includes a statement of key ethical prin-
ciples and values—beginning with ‘the principle of
human dignity, which asserts the principle of
non-commercialisation of the human body’ (Section 1.2).
It also acknowledges some conﬂicts between these values,
namely that ‘the values of freedom and free enterprise can
conﬂict with the principles of solidarity and justice, accord-
ing to which access to justice should be on an equitable
basis’. The Opinion itself focuses on the practical, policy
and legal implications of commercial cord blood banking
in Europe. The raising of expectations and stoking of fears
by promissory advertising, and the possibility of inequit-
able access to future stem cell therapies are particular
concerns, along with potential threats to consumer
safety. Private cord blood banking is shown to be inequit-
able and inefﬁcient from a public health perspective.
To inform their deliberations, the EGE commissioned a
worldwide review of cord blood stem cell banking that
mapped current practices, their organisation and
economic impact (Gunning 2003) and invited representa-
tions from professional groups, clinicians, tissue bankers
and Commission departments via a series of closed
hearings.10 These activities were conducted in the context
of a wider simultaneous discussion in EU institutions
about proposals for Directive 2004/23/EC on the
‘Banking of human tissues and cells and their applica-
tions’. The EGE distilled these representations in the
light of EU policy and law, national statements and
opinions on the issue,11 and ethical traditions, and
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reiterated the most salient concerns in its Opinion. The
Opinion also appears to have given the EGE the oppor-
tunity to reiterate principles that feature in its earlier work,
and to update the context of its declarations.12 The
Opinion was issued to the President and distributed to
Commissioners, Director Generals, MPs, National Ethics
Committees and other key stakeholders, and made
publicly available on its website (Interview (c) 20 June
2007).
In the text of the Opinion, and in our interviews, wider
political resonances and implications were prominent. The
Opinion begins on a critical note:
The legitimacy of commercial cord blood banks for autologous
use should be questioned as they sell a service, which has
presently no real use regarding therapeutic options. Thus they
promise more than they can deliver. The activities of such
banks raise serious ethical criticisms.13 (Section 2.1)
The threat to the normative principles underlying tissue
banking is central to the EGE’s ethical concerns:
Tissue banks were up till now relying on free donation for
treatment to the beneﬁt of other persons or for research, and
by the fact that it implies an act of solidarity or generosity it
contributes to the social cohesion, while the commercial cord
blood banks are running for proﬁt. This reﬂects a more general
shift to a privately funded health care system from a health
system based on solidarity and motivated by public health
considerations, which has characterised Europe in the last
decades. (Section 1.22)
Several of the interviewees referred to the European
values they considered essential in consideration of this
issue, as well as to the international implications of a
free trade in commercial tissue banking. One EGE
member outlined the issues in this way:
I think personally the chief concerns with commercial uses is
that they can help to undermine some important European
values by allowing rich people to buy what they need or what
they think they need, which is not the same thing. Whereas
those with less economic resources may not always be able to
afford what they would in fact need. This is a problem in
Europe, but also [to a] larger extent in the global
perspective . . . So the value at stake here is solidarity . . . trad-
itionally healthcare is and should be based on solidarity and
the idea is that those who need help should get it and that
should be provided for by the national healthcare services.
(Interview (a) 20 June 2007)
The fundamental principle of solidarity and the related
principle of social equity featured prominently among the
values listed by the EGE. To facilitate fair and widespread
access to cord blood transplantation, the use and support
of public cord blood banks was encouraged, not only for
the potential future beneﬁt of the donor and their family
(see Section 2.11), even in exceptional cases of individuals
or families at risk of speciﬁc diseases (see Section 2.9), but
also for that of an increasing multi-ethnic population to
cater for all tissue types, regardless of their ethnic origin
(Section 2.10). To make this viable, the EGE suggested
that increased support for both public cord blood banks
and networks between banks and registries to coordinate
donations is needed to ensure their long-term functioning
(Section 2.12). Consumer protection weighed heavily in
EGE discussions:
I think that we had two main concerns. One, that proper
information is given to the persons [who] are going to use these
banks . . . that the information given should be precise and
explicit in the fact that nobody at this moment has ever used or
very rarely used any of these cells—maybe in the future, but at
this moment there is no precise information. Second, I
think . . . the quality of the cells . . .was one of our main
concerns. The public banks offer very strict control.
(Interview (b) 20 June 2007)
The need to police print media and internet advertising
by commercial cord blood banks, and the adequate control
by public authorities of such advertising (2.5), formed the
core of the EGE’s ethical judgement:
While some members of the Group consider that this activity
should be banned, the majority of the Group considers that the
activities of these banks should be discouraged but that a strict
ban would represent an undue restriction on the freedom of
enterprise and the freedom of choice of individuals/couples.
These banks should operate under strict conditions. (Section
2.2)
The paradox presented by preserving both the freedom
of enterprise and the freedom of choice weighed heavily
against such an opinion being recorded:
[First,] it’s the freedom of activity that has to be preserved and
second, we were aware that some individuals, even if
the . . . correct information is given, . . .want to have the cells
of their children [stored] in a private bank. Some people have
insisted on going abroad . . . against the laws of their own
country. So we have to protect these people . . .why should we
forbid . . . the wish of these people. So most of our members
accepted that we are not able to recommend a complete ban.
(Interview (b) 20 June 2007)
Freedom of choice was underlined by another member as:
an important value in Europe . . .which in this particular case
means that you are or should be, in principle, free to use the
money that you have earned . . . as long as you don’t harm
others or yourself by your actions. . . .This is in principle okay
as long as, and this is important, the basis is free and informed
consent. That is, as long as they have not been misled by the
marketing of the big companies . . . . (Interview (a) 20 June
2007)
The EGE considered it impossible, for ethical and other
reasons, to restrict the movements or choices of consumers
or of commercial enterprises in this context, as in others.14
Instead, strict regulation including licensing and supervi-
sion of the procedures of both public and private banks
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(where legal) by the competent State Authority is recom-
mended (Section 2.3). The EGE also welcomed the Tissues
and Cells Directive that provides an overarching European
legal framework that encompasses both public and com-
mercial cord blood banks (Section 2.6). In concluding, the
Opinion recommends that:
. . . a European debate on the increasing role of the market in
the healthcare system and its advantages and disadvantages
should allow European citizens to be aware of the present
trends and their implications, in particular on the issues raised
in the present opinion. (Section 2.13)
As with earlier pronouncements on tissue banking, in
this Opinion, the EGE is mediating between values of
commerce and enterprise; and of altruism and solidarity.
The Opinion recognises, but fails to confront, the threat
posed by commercial bodies. Instead, it resorts to the sug-
gestion of better information and a public debate to diffuse
concern. The emphasis on provision of information to
consumers as a solution to these policy problems was
also evident in our interviews. (Interview (a) 20 June
2007; Interview (b) 20 June 2007)
4.2 The EGE’s role and influence in a web of
bioethical governance
The web of relations that exists between the EGE and the
Commission, and between other European, national, bio-
ethics, professional and clinical policy networks (see
Fig. 1), provides its members with relative stability and
authority to act on social and ethical concerns. All the
EGE members who contributed to Opinion No. 19 also
held positions on either national, European or professional
bioethics committees. Pere Puigdome`nech Rosell was a
member of the Scientiﬁc Steering Committee of the
Directorate-General for Health and Consumer Protection
at a time (2000–3) when both the Tissues and Cells
Directive and Opinion No. 19 were being developed.
NEC Forum
NECs
Council of
the EU
European
Parliament
Inter
Service
Platform
Civil
Society
Organisat
-ions
EGE
Secretariat GAEIB /EGE
European
Commission
BEPA
Timeline indicating when web links were first established
European Commission establishes 
the GAEIB in 1991, and the EGE in 1997
1998-2000  mandate
2000-2005 mandate
2005-2010  mandate
Figure 1. EGE’s expanding links to a web of bioethical governance in EU.
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These mutually beneﬁcial relationships lend legitimacy to
the authority of the Commission’s politically and morally
contested policies while, arguably, the EGE itself achieves
substantive political cachet from its network of relations.
One member considered the EGE’s inﬂuence within the
Commission to be substantial:
. . . the impact of the EGE is high because they are responding
to a number of requests from the President which means that
there is also from the Commission and from the President’s
side, the awareness that the EGE is an important item in the
policy design. (Interview (c) 20 June 2007)
One curious exception is the lack of identiﬁable inﬂuence
from Opinion No. 19 on EU legislative proposals,
including the Tissues and Cells Directive. The proposal
for the Directive referred explicitly to the earlier Opinion
No. 11 by expressly stating that it ‘reﬂects the recommen-
dations put forth by the EGE’, whose opinion will be
sought and respected in future development of legislation
(European Commission 2002b). The ﬁnal text of the
Directive, especially its preamble, explicitly features
ethical principles found in the earlier Opinion, but does
not speciﬁcally acknowledge a particular Opinion, only
that the Opinions of the EGE have been taken into
account (European Parliament and the Council of the
European Union 2004). The timing and scope of
Opinion No. 19, however, suggests the EGE’s deliber-
ations (between late 2001 and early 2004) overlap substan-
tially with the development of the Directive. The tight
focus of this Opinion—concerned exclusively with one
form of tissue banking—may explain the absence of cit-
ations in legislative proposals, which are more likely to
adopt a broader focus (Busby et al. 2008). Nor did we
ﬁnd speciﬁc evidence of Opinion No. 19 having been
used in the interpretation of hard law. One EGE member
speculated that the Opinion’s lack of inﬂuence was
probably due to its unusually prolonged consideration
(over two-and-a-half years) and eventual publication just
weeks prior to the Directive entering into force (Interview
8 August 2007).
Responsibility for the ethical stance of law and policy on
cord blood banking remains to a considerable extent in the
hands of Member States. Thus, some countries, notably
France and Spain, have been able to take a stronger
stance, prohibiting or constraining commercial cord
blood banking. In Spain, regulations require that any
cells privately stored must be registered and available to
a patient who needs them: they may not be ring fenced for
the exclusive use of the customer and their family (Santoro
2009). However, these national regulations do not prevent
people taking advantage of commercial facilities available
in other countries (European Hematology Association
2007). Both internationally, and in Europe, a number of
facilities exist that provide for both public and private cord
blood storage, sometimes known as ‘hybrid cord banks’
(World Marrow Donor Association 2009). However,
many EU Member States have allowed commercial cord
banking to continue, albeit with the more rigorous quality
controls that are now required by the Tissues and Cells
regulatory framework.
Nonetheless, Opinion No. 19 appears to have had some
inﬂuence internationally. Policies and guidelines issued by
national networks of professionals, bioethicists and public
sector tissue banks have cited it to question the legitimacy
of commercial banking practices. For instance, Opinion
No. 19 has informed several subsequent opinions by
National Ethics Committees on umbilical cord blood
banking, including those published by the Austrian
Bioethics Commission (Gu¨nter Virt was invited to
address the Health Ministry on the EGE’s Opinion
(Interview 19 June 2007) (Bundeskanzleramt O¨sterreich
2008)) and the Swedish National Council on Medical
Ethics (through the joint participation of Go¨ran
Hermere´n in the Council and the EGE) (Swedish
National Council on Medical Ethics 2005). In the UK,
the Opinion has been cited by the Royal College of
Obstetricians and Gynaecologists (Royal College of
Obstetricians and Gynaecologists 2006), the Royal
College of Midwives and by NHS Trusts. In this sense, it
may also have provided an interpretative reference point
for the conduct of individuals—for instance, clinicians,
parents and commercial bodies. After the publication of
the Opinion, some EGE members were contacted person-
ally by interested parties from Spain, Uruguay and
Argentina (Interview (b) 20 June 2007), by midwives con-
cerned about the process of cord blood collection
(Interview 24 October 2007), and by civil servants, the
Red Cross and commercial bank shareholders (Interview
19 June 2007).
Some interviewees thought that the Opinion had been
‘passively inﬂuential’ (Interview 24 October 2007) on
Member States who deal with such blood banks, and in
terms of contributing to self-regulation by commercial
banks (Interview (a) 20 June 2007), by drawing attention
to the advertising claims of private banks where a recent
shift emphasising that parents were paying for storage
rather than a service was noted (Interview 8 August
2007; Interview 19 June 2007). One member judged that
the Opinion ‘certainly played a role’ in the decision to es-
tablish a public rather than a private cord blood bank in
his home country after he had debated the issue on televi-
sion and in the national Medical Association and Council
on Medical Ethics (Interview (a) 20 June 2007).
5. Conclusion: A legitimating role?
This paper set out to consider the contribution of the EGE,
as an integral component of a web of governance, to the
governance of tissue banking within the EU, and thus the
extent to which the EGE might be said to contribute to
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the democratic legitimacy of EU institutions. One
document that has been particularly inﬂuential in
framing discussions on legitimacy within the EU is the
2001 White Paper on European Governance (European
Commission 2001). The White Paper proposed to
address the democratic deﬁcit by fostering greater
openness, participation, accountability, effectiveness and
coherence. Responding to a commitment made in the
White Paper to publish guidelines on the collection and
use of expert advice, a Commission Communication
seeks to establish a sound knowledge base for better
policies and a credible process of collecting and using
expert advice (European Commission 2002a). The
Communication establishes three core principles for
better governance (which in the EU context double as
norms of legitimacy)—quality, openness and effective-
ness—that apply to all expert groups, whether ad hoc or
permanent, who advise the Commission during the policy
process. Quality is deﬁned in terms of expert advice
underpinned by excellence, independence and pluralism.
Openness is deﬁned as transparency and accountability
of expert advice. Effectiveness is deﬁned in terms of costs
and proportionality of expert input into policy decisions;
ergo, in terms of efﬁciency.
These principles of quality, openness and effectiveness
set a practical framework for the EGE’s activities: its
mandates, membership, and working methods; its relation-
ship with European decision-makers, stakeholders and
publics. We now conclude whether or not the EGE’s
processes and advice (contained in its Opinions) can be
considered to embody quality, openness and effectiveness,
broadening the legitimacy base of EU decisions on ethic-
ally contentious technologies.
5.1 Quality, openness and effectiveness of expert
ethical advice?
Since its inception as the GAEIB, the EGE has sought to
provide ‘neutral, independent, pluralist and multidisciplin-
ary’ advice to EU decision-makers on the ethical dimen-
sions of biotechnologies. EGE members are distinguished
by their internationally recognised expertise in their re-
spective ﬁelds and their high-level experience on a range
of national, European and professional bioethics advisory
bodies. By increasing the range of knowledge-based expert
opinions, it is assumed that genuinely authoritative—as
well as legitimate—decisions are reached. Yet professional
bioethics, such as that embodied by the EGE, has been
criticised for drawing on a limited range of experience, as
well as a narrow repertoire of arguments (Scully et al.
2006; Engelhardt 2011). The inclusion of lay bioethics
through deliberation can illuminate areas of moral import-
ance that professional ethics is likely to miss (Salter and
Jones 2005). The bounding of value debates by profes-
sional ethicists reinforces a reductionist view of ignorant,
incompetent publics.
The use of a consensus approach, whereby ethical reﬂec-
tion on a range of values is used to determine unanimous
value judgements, is seen as a way for bioethics advisory
bodies to contain and stabilise the tensions that exist at the
boundary between science and politics (Kelly 2003). The
fact that the EGE’s ethical judgement is integrated across
many divergent ﬁelds of expertise, each with their own
traditions of transparency and accountability, can help
to mask underlying philosophical issues and uncertainties,
and exclude alternative risk framings, thus leaving the
EGE vulnerable to charges of ‘groupthink’ (Leinhos
2005; Jasanoff 2009).
The EGE has created its own rules of procedure that
render it relatively opaque even within the Commission,
and to Parliament and the wider European citizenry,
which exempts it from normal channels of political and
public accountability. Adding new forms of expertise
with each subsequent mandate may help to increase the
credibility of the EGE, but has not fully addressed issues
of accountability, where high standards of integrity (trans-
parency and trust) must be upheld in the relations between
the EGE and European decision-makers, stakeholders and
publics. If EGE members claim to represent only ‘them-
selves’, to whom are they politically accountable? Who are
their ethical ‘constituents’?
In the case of Opinion No. 19, few concessions to
openness were made. Developed before public round-table
debates to promote dialogue and improve transparency
became a statutory requirement for the EGE, it relied
on closed hearings involving professional groups, clin-
icians, tissue bankers and Commission departments
to broaden the value base. Only soliciting the opinions
of experts, and not widely consulting the public for add-
itional moral points of view falls short of satisfying
the norms of legitimacy embodied by the Commission’s
principles for better governance. Concerned with
balancing the tension between achieving transparency
and efﬁciency, the EGE’s recent adoption of public
round tables (albeit limited to those disposed to travel to
the venue) signals a growing concession to transparency
balanced against long periods of closed discussion to facili-
tate the efﬁcient exchange of views as well as allowing
members to change their views over time (Interview 24
October 2007).
The fact that the EGE’s members are appointed by
the President may be an indication of the priority of
its issues for the EU policy-making agenda: an indication
of its political legitimacy. On the other hand, the fact
that the European Parliament can also request opin-
ions points to a broader role and responsibility for the
EGE: one where public legitimacy is also required to
satisfy the conditions of its mandate. Rather than be
used as ‘instruments for public awareness’ (as described
by a member of the EGE (Capurro 2005)) bioethics
advisory bodies such as the EGE could, and perhaps
should, function as deliberative spaces for public moral
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discourse, legitimately serving goals related to both public
and political interests. Plomer (2008: 858–9) suggests the
EGE could:
. . .make a useful contribution to deliberative engagement with
ethical questions in Europe if it were to operate as a
deliberative chamber.
Bioethics advisory bodies that do not engage with
broader lay values can be seen to not adequately represent
the public interest and therefore lack a broader public
legitimacy.
We conclude by reiterating that the EGE, as an integral
component of a web of bioethical governance, has played a
demonstrable role in inﬂuencing policies and positions
relating to the commercialisation of cord blood banking
in the EU and further aﬁeld. However, the extent to which
the EGE’s activities and its advice can be considered to
embody principles of quality, openness and effectiveness,
and thus broaden the legitimacy base of EU decisions, is
only partial. The EGE’s mandate ‘to promote dialogue
that stimulates mutual tolerance so that all viewpoints
can be expressed’, points to a broader role and responsi-
bility. Yet the opacity of the EGE’s working methods, as
was the case for its Opinion on commercial cord blood
banking, fails to satisfy the conditions of its mandate as
well as those required for public legitimacy. Likewise, the
EGE’s elite membership and narrow repertoire of ethical
arguments excludes and masks alternative views. On
this basis, the EGE has largely failed to contribute to
the democratic legitimacy and accessibility of EU
decision-making processes on ethically contentious
technologies. In this respect, charges of a democratic
deﬁcit persist.
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Notes
1. See Communication on promoting the competitive en-
vironment (European Commission 1991: 1–2), where
the Commission emphasised the need for ethical dis-
cussions on the development of biotechnology: ‘it is
imperative that problems of public acceptability, and
ethical questions raised, be recognised and dealt with.
It is suggested that there should be advice available to
the Commission in the area of ethics in
biotechnology’.
2. Two other interviews with EGE members were
planned but were unable to be scheduled. The ﬁrst
was due to the member’s death, while the second
failed to respond to our requests for an interview.
3. Opinion No. 3 on the ‘Ethical questions arising from
the Commission proposal for a Council Directive for
legal protection of biotechnological inventions’ and
Opinion No. 8 on the ‘Ethical aspects of patenting
inventions involving elements of human origin’. The
Directive also acknowledges that ‘account has been
taken of Opinion No. 8’. Later, Opinion Nos. 9 and
10 also address ethical issues relevant to the
Biotechnology Directive and were published prior to
the Directive’s publication.
4. Although, this position is less clear in the legislative
texts on which the EGE is based, in which the access of
the other institutions to the EGE is mediated through
the Commission.
5. These include public health, research, international
affairs, biotechnology, legal services (Interview (c) 20
June 2007).
6. Although one of our interviewees stated that members
are required to declare any conﬂict of interest
(Interview (c) 20 June 2007).
7. This point was also emphasised in many of our inter-
views: (Interview 8 August 2007; Interview 18 October
2007; Interview 19 June 2007; Interview (a) 20 June
2007; Interview (b) 20 June 2007). One interviewee
questioned the word ‘representing’ itself (Interview
19 November 2007).
8. For instance, the EGE participates in the Forum of
National Ethics Councils, where all 27 Member States
are represented. The work of the UK Nufﬁeld
Foundation was mentioned as particularly useful or
inﬂuential (Interview (b) 20 June 2007; Interview (c)
20 June 2007).
9. This view is expressed in many European codes of
ethics, including the Oviedo Convention, and is re-
ﬂected in the political discussions about the uses of
human tissues, notably of Directive 98/44/EC
(European Parliament and the Council of the
European Union 1998) and Directive 2004/23/EC
(European Parliament and the Council of the
European Union 2004).
10. Hearings of experts and Commission departments
were held on 16 September 2003, 18 November 2003
and 16 December 2003 in Brussels and 20 October
2003 in Rome.
11. The preamble to Opinion No. 19 states, ‘Having
regard to the opinions expressed by national instances
on that issue, namely the Opinion No. 74 of 12
December 2002 of the National Consultative Ethics
Committee on umbilical cord blood banks for
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autologous use or for research (France), the statement
by the Belgian Medical Association addressed to gy-
naecologists and general practitioners, the opinion
paper of October 2001 of the Scientiﬁc Advisory
Committee of the Royal College of Obstetricians and
Gynaecologists (UK), the opinion of 7th December
2001 of the Belgian Health Council on the revision
of tissue banks’ legislation and the American
Academy of Paediatrics’ recommendations of 14th
July 1999’ (EGE 2004).
12. Opinion No. 11 (1998) on the ‘Ethical aspects of
human tissue banking’ and Opinion No. 15 (2000)
on ‘Ethical aspects of human stem cell research and
use’ addressed concerns such as the imperative to
support public sector tissue banking, to constrain the
activities of commercial organisations in this domain,
and to continue to develop regulations to protect
consumer safety, within a public health framework.
13. Cryo-Cell responded angrily to this point, perceiving it
to be an attack on its commercial viability (Interview
24 October 2007).
14. While regulation of manufacture of blood and tissue
products was under way at the EU level, systems for
tissue donation and banking per se continued to be
squarely in the competence of health systems in indi-
vidual states—albeit that the need for coordination
was becoming more evident (Farrell 2006). Private
cord banks seemed to fall on the cusp of these
various regulatory distinctions.
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